Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to indivi...
Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Monoclonal antibodies (Mabs) have become key drugs in cancer treatment, either as targeted therapies or more recently as immune checkpoint inhibitors (ICIs). The fact that only some patients benefit from these drugs poses the usual question in the field of onco‐hematology: that of the benefit of individual dosing and the potential of therapeutic dr...
Alternative Titles
Full title
Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_de932d7a0fe14f119b38e5a85bccf4de
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_de932d7a0fe14f119b38e5a85bccf4de
Other Identifiers
ISSN
2052-1707
E-ISSN
2052-1707
DOI
10.1002/prp2.757
